Q-omics provides the consensus-scored LINC01507 profile across patient tissues and cancer cell-line models. LINC01507 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01507 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, LINC01507 RNA expression shows 12,502 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where LINC01507 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01507 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01507 survival associations across molecular data types. LINC01507 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01507 RNA expression–survival associations across cancer types. High LINC01507 expression shows unfavorable associations in COAD, STAD, ACC and DLBC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01507 RNA expression.
This table summarizes LINC01507 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01507. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01507 shows lower tumor expression in KICH, LIHC, KIRC and THCA and higher tumor expression in BRCA and LUAD. The KICH box plot shows higher LINC01507 RNA expression in normal versus tumor tissue (log2 FC = −2.191, t-test p < 0.001).
This table shows molecular features associated with LINC01507 in patient tissues and cancer cell lines. In patient samples, LINC01507 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
